Study of 1,3-Butanediol Ketone Supplements for Adults Hospitalized with Acute Heart Failure to Improve Clinical Outcomes

What this Trial Is About

Researchers are investigating the effects of an exogenous dietary ketone supplement containing 1,3-butanediol in patients hospitalized with acute heart failure AHF. Acute heart failure is a serious condition with high mortality rates, and current treatments have not significantly improved survival. This study aims to see if 1,3-butanediol can improve clinical outcomes by supporting heart energy use and function during acute episodes. Participants will be randomly assigned to receive either 1,3-butanediol Ketone-IQae or a taste-matched placebo. Both treatments are given as 118 mL servings three times daily for 30 days. The study is double-blind, meaning neither participants nor researchers know who receives the supplement or placebo. The trial includes a 30-day treatment period to compare the effects on heart function and patient health. Throughout the study, participants will undergo assessments of clinical benefit including death, heart failure events, and changes in physical performance measured by a six-minute walk test and NT-proBNP levels. Other evaluations include daily activity, heart function scores, symptoms, blood pressure, weight, medication use, and need for intensive care or dialysis. Safety and efficacy will be monitored closely during the 30-day treatment period to understand how the supplement affects acute heart failure outcomes.

Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure